Abstract:RNA interference (RNAi) presents great potential against intractable liver diseases. However, the establishment of specific, efficient, and safe delivery systems targeting hepatocytes remains a great challenge. Herein, we described a promising hepatocytes-targeting system through integrating triantennary N-acetylgalactosamine (GalNAc)-engineered cell membrane with biodegradable mesoporous silica nanoparticles, which efficiently and safely delivered siRNA to hepatocytes and silenced the target PCSK9 gene expression for the treatment of non-alcoholic fatty liver disease. Having optimized the GalNAc-engineering strategy, insertion orders, and cell membrane source, we obtained the best-performing GalNAc-formulations allowing strong hepatocyte-specific internalization with reduced Kupffer cell capture, resulting in robust gene silencing and less hepatotoxicity when compared with cationic lipid-based GalNAc-formulations. Consequently, a durable reduction of lipid accumulation and damage was achieved by systemic administering siRNAs targeting PCSK9 in high-fat diet-fed mice, accompanied by displaying desirable safety profiles. Taken together, this GalNAc-engineering biomimetics represented versatile, efficient, and safe carriers for the development of hepatocyte-specific gene therapeutics, and prevention of metabolic diseases. STATEMENT OF SIGNIFICANCE: Compared to MSN@LP-GN3 (MC3-LNP), MSN@CM-GN3 exhibited strong hepatocyte targeting and Kupffer cell escaping, as well as good biocompatibility for safe and efficient siRNA delivery. Furthermore, siPCSK9 delivered by MSN@CM-GN3 reduced both serum and liver LDL-C, TG, TC levels and lipid droplets in HFD-induced mice, resulting in better performance than MSN/siPCSK9@LP-GN3 in terms of lipid-lowering effect and safety profiles. These findings indicated promising advantages of our biomimetic GN3-based systems for hepatocyte-specific gene delivery in chronic liver diseases. Our work addressed the challenges associated with the lower targeting efficiency of cell membrane-mimetic drug delivery systems and the immunogenicity of traditional GalNAc delivery systems. In conclusion, this study provided an effective and versatile approach for efficient and safe gene editing using ligand-integrated biomimetic nanoplatforms.

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity

Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates

Ligand conjugate SAR and enhanced delivery in NHP

Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference

Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates

Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy

The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate

Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease

Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease

In Vivo Efficacy and Off-Target Effects of Locked Nucleic Acid (LNA) and Unlocked Nucleic Acid (UNA) Modified Sirna and Small Internally Segmented Interfering RNA (sisirna) in Mice Bearing Human Tumor Xenografts

Sirna Design And Galnac-Empowered Hepatic Targeted Delivery

Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases

Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics

Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)